EOFLOW Co.,Ltd. Stock price
Equities
A294090
KR7294090006
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
4,860 KRW | -5.45% | -48.90% | -67.60% |
Dec. 06 | Medtronic Korea Holdings Co., Ltd. cancelled the acquisition of 18.54% stake in EOFLOW Co.,Ltd. from Jaejin Kim. | CI |
May. 29 | US-based Medtronic Acquires EOFlow | MT |
Sales 2022 | 6.71B 5.08M | Sales 2023 * | - | Capitalization | 455B 345M |
---|---|---|---|---|---|
Net income 2022 | -30.71B -23.28M | Net income 2023 * | - | EV / Sales 2022 | 62,1x |
Net cash position 2022 | 38.12B 28.9M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
P/E ratio 2022 | -14,6x | P/E ratio 2023 * | Employees | - | |
Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 80.31% |
More Fundamentals
* Assessed data
More news
1 day | -5.45% | ||
1 week | -48.90% | ||
Current month | -41.38% | ||
1 month | -77.60% | ||
3 months | -80.83% | ||
6 months | -82.83% | ||
Current year | -67.60% |
1 week
4 740.00
11 450.00

1 month
4 740.00
17 420.00

Current year
4 740.00
29 150.00

1 year
4 740.00
29 150.00

3 years
4 740.00
42 150.00

5 years
4 740.00
42 150.00

10 years
4 740.00
42 150.00

Managers | Title | Age | Since |
---|---|---|---|
Jesse J. Kim
FOU | Founder | 62 | - |
Luis J. Malavé
PSD | President | 60 | 2017 |
Ian G. Welsford
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jesse J. Kim
FOU | Founder | 62 | - |
Dong-Il Jo
BRD | Director/Board Member | 65 | - |
Kyung-Jun Lee
BRD | Director/Board Member | 60 | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-10 | 4,860 | -5.45% | 8 017 049 |
23-12-08 | 5,140 | -28.71% | 20,314,870 |
23-12-07 | 7,210 | -29.93% | 216,377 |
23-12-06 | 10,290 | -6.88% | 336,006 |
23-12-05 | 11,050 | +16.32% | 1,162,701 |
End-of-day quote Korea Stock Exchange, December 10, 2023
More quotes
EOFlow Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medical devices. The Company's main products include wearable insulin pumps, insulin infusion regulators for blood sugar control in diabetic patients.
Calendar
2024-03-12
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-67.60% | 119 M $ | |
+0.47% | 8 647 M $ | |
-18.29% | 6 427 M $ | |
+3.74% | 6 029 M $ | |
-31.26% | 5 515 M $ | |
+29.21% | 5 276 M $ | |
+6.50% | 4 610 M $ | |
-3.51% | 3 631 M $ | |
+28.86% | 3 551 M $ | |
-27.45% | 2 423 M $ |